Press release
Angioedema Treatment Market Revenue Opportunies By Key Vendors Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals
Angioedema-Treatment-Industry
Frequent approval of novel drugs from regulatory bodies is expected to boost growth of global angioedema treatment market.
Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1371
In 2017, U.S. Food and Drug Administration approved Haegarda, a C1 Esterase Inhibitor (Human) for subcutaneous administration indicated for the preventing hereditary angioedema (HAE) in adult and adolescent patients. In 2014, Pharming Group NV and Salix Pharmaceuticals, Ltd. received US Food and Drug Administration (FDA) approval for RUCONEST (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, indicated for the treatment of acute angioedema attacks in adult and adolescent patients with HAE. In 2016, CSL Behring received FDA approval for Berinert [C1 Esterase Inhibitor (Human)], indicated for the treatment of HAE attacks in pediatric patients. These multiple approvals of new drugs by regulatory bodies are expected to drive growth of global angioedema treatment market over the forecast period. Furthermore, initiatives taken by various organizations to support treatment of angioedema is also expected to support the growth of global angioedema treatment market. For instance in 2015, British Society for Allergy and Clinical Immunology (BSACI) provided a guideline for the management of chronic urticaria and angioedema. In 2013, the World Allergy Organization (WAO) also provided guideline for the Management of Hereditary Angioedema.
Competitive Landscape of Angioedema Treatment Market:
Key players in angioedema treatment market include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. In 2017, Shire plc. received European Commission (EC) approval for label extension, that increases indication for FIRAZYR (icatibant injection), broadening use to adolescents and children aged 2 years and older, with HAE caused by C1-esterase-inhibitor (C1-INH) deficiency.
Europe angioedema treatment market is expected show significant growth, owing to increasing presence of angioedema drug manufacturers.
Request for Customization of Research Report:
https://www.coherentmarketinsights.com/insight/request-customization/1371
Angioedema Treatment Market Taxonomy:
The angioedema treatment market is segmented on the basis of condition type, drug type, route of administration, distribution channel, and geography
By Condition Type:
• Allergic angioedema
• Drug-induced angioedema
• Idiopathic angioedema
• Hereditary angioedema (HAE)
By Drug Type:
• C1 esterase inhibitor
• Cinryze
• Berinert
• Ruconest
• Haegarda
• Selective bradykinin B2 receptor antagonist
• Firazyr
• Kallikrein inhibitor
• Kalbitor
• Others
By Route of Administration:
• Injection
• Intravenous
• Subcutaneous
• Oral
By Distribution Channel
• Hospitals
• Retail pharmacies
• Online pharmacies
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Angioedema Treatment Market Revenue Opportunies By Key Vendors Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals here
News-ID: 1265180 • Views: …
More Releases from Coherent Market Insights - Pharmaceutical Industry
Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.
Ask For Sample Copy of Research…
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development.
Ask For a Sample Copy of This Business Report @…
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players.
Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976
Market…
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around…
More Releases for Angioedema
Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033.
Hereditary Angioedema Market Overview
The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
Angioedema Treatment Market 2022 | Detailed Report
This report provides an informative view about the competitive aspect of the global market. It includes detailed picture of the exhibition of a portion of the essential global players working in the Angioedema Treatment market. The research study also provides historical record with profits predictions and forecasts from 2022 to 2028. Also, the business manufacturing of the notable manufacturers is also emphasized with technical data in the report.
This report is…
Hereditary Angioedema Therapeutics Market - Forecast to 2026
As per the research conducted by GME, the Global Hereditary Angioedema Therapeutics Market will grow with a CAGR value of 8.2%. Population growth, as well as lifestyle changes, improved insurance programs, and increased efforts by pharmaceutical and biotechnology companies to develop new products and solutions for the industry, are expected to fuel market revenue for Hereditary Angioedema in the years ahead.
Browse 153 Market Data Tables and 113 Figures spread through…
